# A Study to Test Different Doses of BI 3923948 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)

> **NCT07395258** · PHASE1 · RECRUITING · sponsor: **Boehringer Ingelheim** · enrollment: 60 (estimated)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** BI 3923948
- **DRUG:** Ezabenlimab

## Key facts

- **NCT ID:** NCT07395258
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-02
- **Primary completion:** 2028-02-20
- **Final completion:** 2032-02-12
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07395258

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07395258, "A Study to Test Different Doses of BI 3923948 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07395258. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*